A Trial of SHR-3792 Injection in Patients With Advanced Solid Tumors
The study is being conducted to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of SHR-3792 injection monotherapy for patients with advanced solid tumors, and to explore the reasonable dosage of SHR-3792 injection monotherapy for patients with advanced solid tumors.
| Condition(s) | Advanced Solid Tumors |
|---|---|
| Status | Recruiting |
| Phase | Phase 1 |
| Study type | Interventional |
| Summary | The study is being conducted to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of SHR-3792 injection monotherapy for patients with advanced solid tumors, and to explore the reasonable dosage of SHR-3792 injection monotherapy for patients with advanced solid tumors. |
| Who can participate | Inclusion Criteria: 1. Subjects with ability to understand and voluntarily agree to participate by giving written informed consent form for the study. 2. Patients with unresectable recurrent or metastatic solid tumors. 3. There is at least one lesion that could be measured. 4. An Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1. 5. Adequate organ functions as defined. 6. Life expectancy ≥ 3 months. Exclusion Criteria: 1. Patients with known active central nervous system (CNS) metastases. 2. Subjects with other malignancy in five years before the first dose. 3. Patients with tumor-related pain that cannot be controlled as determined. 4. Patients with serious cardiovascular and cerebrovascular diseases. 5. Uncontrollable third-space effusion, such as pleural |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Lead sponsor | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| Locations | Jinan, Shandong, China |
| Start date | 2025-04-02 |
| NCT ID | NCT06907628 |
| Official listing | https://clinicaltrials.gov/study/NCT06907628 |